A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma

Abstract Background Uterine serous carcinoma and carcinosarcoma are aggressive forms of endometrial cancer with poor survival outcomes. Trastuzumab, a human epidermal growth factor receptor-2 (HER2)-directed monoclonal antibody, has demonstrated tumoricidal efficacy. However, clinical data regarding...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ting-Fang Lu, Lou Sun, Yu-Hsiang Shih, Yen-Fu Chen, Chun-Ting Fan, Shao-Jing Wang, Shih-Tien Hsu, Chih-Ku Liu, Sheau-Feng Hwang, Chien-Hsing Lu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-02-01
Edice:	BMC Medicine
Témata:	Uterine serous carcinoma Uterine carcinosarcoma Human epidermal growth factor receptor 2 Trastuzumab
On-line přístup:	https://doi.org/10.1186/s12916-025-03916-3
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!